Abstract
Merck & Co. will pay $2.75 billion to acquire the private San Diego–based cancer firm VelosBio, which is developing antibody drugs that target tyrosine kinase–like orphan receptor 1 (ROR1). VelosBio’s most advanced candidate is an antibody-drug conjugate (ADC) that targets ROR1—found on some cancer cells but not healthy adult cells—and unleashes a toxic agent called monomethyl auristatin E. Three approved ADCs use the same toxic agent. VelosBio began a Phase 2 trial of its ADC in October. The firm also has a preclinical bispecific antibody that targets ROR1 and recruits immune cells to destroy the tumor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
